Drugs Made In America Acquisition DMAA
- Market cap
- $264.3M
- Revenue, 12 months
- n/m
- not a meaningful number
Charts
Financials
| Income statement | Q3 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|
| SG&A | $144.9K | $330.9K | $131.9K | $263.7K | $2.1M | $143.3K−57% | $136.9K+4% |
| −$144.9K | −$330.9K | −$131.9K | −$263.7K | −$2.1M | −$143.3K−57% | −$136.9K+4% | |
| Net income | −$144.9K | $1.3M | $2.3M | $2.2M | $213K | $2M+57% | $1.7M−25% |
| −$0.02 | $0.05 | $0.07 | $0.07 | $0.02 | $0.06+20% | $0.06−14% | |
| 8.6M | 10.3M | 10.5M | 10.5M | 11.2M | 10.7M+4% | 10.7M+2% |
EPS, diluted: Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Financial Services nearest Drugs Made In America Acquisition's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| DMAADrugs Made In America Acquisition | $264.3M | n/m | 50.2× | n/m | n/m | n/m | |
| RMBIRichmond Mutual Bancorporation | $264.6M | 13.0× | 13.1× | n/m | +15% | 23.1% | |
| NKSHNational Bankshares | $261M | 12.9× | 16.4× | n/m | +21% | 33.6% | |
| HWBKHawthorn Bancshares | $271.5M | 10.7× | 10.2× | n/m | +12% | 30.0% | |
| SNFCASecurity National Financial | $254.1M | 6.4× | 5.8× | 0.8× | −1% | 11.1% | |
| POWWOutdoor | $279.6M | 80.3× | 21.7× | 5.2× | +10% | 6.4% | |
| EFSIEagle Financial Services | $248.6M | 13.3× | 11.3× | n/m | +37% | 20.6% | |
| WNEBWestern New England Bancorp | $281.8M | 16.7× | 16.4× | n/m | +17% | 19.0% | |
| FXNCFirst National | $283.6M | 13.1× | 10.8× | n/m | +12% | 23.3% | |
| LCNBLCNB | $285.1M | 11.6× | 11.7× | n/m | +9% | 25.5% | |
| VABKVirginia National Bankshares | $286.5M | 11.6× | 12.1× | n/m | +13% | 39.0% | |
| Peer median | $275.5M | 13.0× | 11.9× | 3.0× | +13% | 23.2% |
More on Drugs Made In America Acquisition
Each number over time
Its groups
About
- Industry
- Shell Companies
- Sector
- Financial Services
Valuation data, not investment advice. Prices as of .